Drug name - Osphena

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9566252 DUCHESNAY Method for the alleviation of dyspareunia in women Nov, 2022

(a month from now)

US8470890 DUCHESNAY Method for enhancing the bioavailability of ospemifene Feb, 2024

(1 year, 4 months from now)

US8772353 DUCHESNAY Method for enhancing the bioavalability of ospemifene Feb, 2024

(1 year, 4 months from now)

US9855224 DUCHESNAY Method for enhancing the bioavailability of ospemifene Feb, 2024

(1 year, 4 months from now)

US9241915 DUCHESNAY Method for enhancing the bioavailability of ospemifene Feb, 2024

(1 year, 4 months from now)

US6245819 DUCHESNAY Method for the treatment of vaginal dryness and sexual dysfunction in women during or after the menopause Jul, 2025

(2 years from now)

US8236861 DUCHESNAY Method for enhancing the bioavailablity of ospemifene Aug, 2026

(3 years from now)

US8642079 DUCHESNAY Solid formulations of ospemifene Jul, 2028

(5 years from now)

Drugs and Companies using OSPEMIFENE ingredient

Treatment: Treatment of dyspareunia associated with menopause; Treatment of moderate to severe vaginal dryness and pain with intercourse, symptoms of vulvar and vaginal atrophy, associated with menopause; treatment of dyspareunia associated with menopause; treatment of vaginal symptoms of urogenital atrophy by orally administering ospemifene with food to enhance bioavailability of ospemifene; Treatment of dyspareunia associated with menopause; treatment of moderate to severe vaginal dryness and pain with intercourse, symptoms of vulvar and vaginal atrophy, associated with menopause; treatment of vaginal symptoms of urogenital atrophy by orally administering ospemifene with food to enhance bioavailability of ospemifene; Treatment of vaginal symptoms of urogenital atrophy by orally administering ospemifene with food to enhance bioavailability of ospemifene; treatment of dyspareunia associated with menopause; treatment of moderate to severe vaginal dryness and pain with intercourse, symptoms of vulvar and vaginal atrophy, associated with menopause; Treatment of moderate to severe vaginal dryness and pain with intercourse, symptoms of vulvar and vaginal atrophy, associated with menopause; treatment of dyspareunia associated with menopause; Treatment of moderate to severe vaginal dryness and pain with intercourse, symptoms of vulvar and vaginal atrophy, associated with menopause; treatment of vaginal symptoms of urogenital atrophy by orally administering ospemifene with food to enhance bioavailability of ospemifene; treatment of dyspareunia associated with menopause

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
60MG TABLET;ORAL Prescription

availability in other generic markets.

Click on the highlighted region to filter.